1.
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19
by Ward, Brian J
Nature medicine, 2021, Vol.27 (6), p.1071-1078
2.
Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data
by Munoz, Flor M
Vaccine, 2021, Vol.39 (22), p.3053-3066
3.
4.
Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines
by Dubé, Charlotte
Vaccine, 2022, Vol.40 (30), p.4017-4025
5.
Therapeutic activity of a Salmonella-vectored Schistosoma mansoni vaccine in a mouse model of chronic infection
by Hassan, Adam S
Vaccine, 2021, Vol.39 (39), p.5580-5588
6.
Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines
by Ward, Brian J
Vaccine, 2014, Vol.32 (46), p.6098-6106
7.
8.
Seroprevalence of rubella antibodies and determinants of susceptibility to rubella in a cohort of pregnant women in Canada, 2008–2011
by Gilbert, Nicolas L
Vaccine, 2017, Vol.35 (23), p.3050-3055
9.
Morphological characterization of a plant-made virus-like particle vaccine bearing influenza virus hemagglutinins by electron microscopy
by Lindsay, Brianne J
Vaccine, 2018, Vol.36 (16), p.2147-2154
10.
Characterization of the innate stimulatory capacity of plant-derived virus-like particles bearing influenza hemagglutinin
by Won, So-Yoon
Vaccine, 2018, Vol.36 (52), p.8028-8038
11.
12.
13.
14.
15.
A multimodal intervention increases influenza vaccine uptake in rheumatoid arthritis
by Valerio, Valeria
Clinical rheumatology, 2020, Vol.40 (2), p.575-579
16.
Low levels of detectable pertussis antibody among a large cohort of pregnant women in Canada
by Brooks, James I
Vaccine, 2018, Vol.36 (41), p.6138-6143
17.
Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice
by Yam, Karen K
Vaccine, 2016, Vol.34 (12), p.1444-1451
18.
Approved but non-funded vaccines: Accessing individual protection
by Scheifele, David W
Vaccine, 2013, Vol.32 (7), p.766-770
19.
Immunologic characterization of a novel inactivated nasal mumps virus vaccine adjuvanted with Protollin
by Young, Katie R
Vaccine, 2013, Vol.32 (2), p.238-245
20.
High Level Antibody Avidity is Achieved in HIV-Seropositive Recipients of an Inactivated Split Adjuvanted (AS03A) Influenza Vaccine
by Yam, Karen K
Journal of clinical immunology, 2014, Vol.34 (6), p.655-662
